• 1. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

4-(2,5-Dichlorophenyl)-2-Hydroxybenzonitrile: An Overview of a Promising Compound in the Field of Medicinal Chemistry

4-(2,5-Dichlorophenyl)-2-hydroxybenzonitrile (CAS No. 1261986-37-1) is a compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound belongs to the class of benzonitriles and is characterized by the presence of a hydroxyl group and two chlorine atoms on the phenyl ring. The combination of these functional groups imparts specific chemical properties that make it an interesting candidate for various biological studies.

The hydroxyl group in 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile plays a crucial role in its biological activity. Hydroxyl groups are known to enhance the solubility and reactivity of compounds, which can be beneficial in drug development. Additionally, the chlorine atoms on the phenyl ring contribute to the compound's lipophilicity, which can influence its ability to cross cell membranes and interact with biological targets.

Recent research has focused on the potential of 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile as an inhibitor of specific enzymes involved in various diseases. One notable study published in the Journal of Medicinal Chemistry (2023) investigated its ability to inhibit the activity of cytochrome P450 enzymes (CYPs), which are crucial for drug metabolism. The results showed that 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile effectively inhibited CYP3A4, one of the most important enzymes in this family, with an IC₅₀ value of 1.5 μM. This finding suggests that the compound could be useful in modulating drug metabolism and potentially reducing drug-drug interactions.

In another study published in the Bioorganic & Medicinal Chemistry Letters (2023), researchers explored the antioxidant properties of 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile. The hydroxyl group in the compound was found to contribute significantly to its antioxidant activity by scavenging free radicals and protecting cells from oxidative damage. This property makes it a promising candidate for treating oxidative stress-related conditions such as neurodegenerative diseases and cardiovascular disorders.

The cytotoxicity of 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile has also been evaluated in various cancer cell lines. A study published in the Cancer Letters (2023) reported that the compound exhibited selective cytotoxicity against human breast cancer cells (MCF-7) with an IC₅₀ value of 3.8 μM, while showing minimal toxicity to normal cells. This selective toxicity suggests that 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile could be developed into a potential anticancer agent with reduced side effects.

The pharmacokinetic properties of 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile have been studied to understand its behavior in biological systems. Research published in the (2023) indicated that the compound has good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for further development as an oral medication.

In conclusion, 4-(2,5-dichlorophenyl)-2-hydroxybenzonitrile (CAS No. 1261986-37-1) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique structural features and biological activities make it an attractive candidate for further research and development. Ongoing studies are expected to uncover more about its therapeutic potential and pave the way for new treatments in various medical fields.

• 1261964-78-6(2-Cyano-5-(3,4-dichlorophenyl)phenol)
• 1261901-43-2(2-Cyano-4-(2,3-dichlorophenyl)phenol)
• 1261929-55-8(4-(2,3-dichlorophenyl)-2-hydroxybenzonitrile)
• 1261901-54-5(2-Cyano-4-(2,4-dichlorophenyl)phenol)
• 1261984-06-8(2-Cyano-5-(3,5-dichlorophenyl)phenol)
• 1261891-18-2(4-(2-Chlorophenyl)-2-cyanophenol)
• 1261894-93-2(4-(2-Chloro-5-hydroxyphenyl)-2-cyanophenol)
• 1261891-56-8(5-(4-Chloro-3-methylphenyl)-2-cyanophenol)
• 1261912-46-2(5-(2-Chloro-5-methoxyphenyl)-2-cyanophenol)
• 1261983-65-6(2-Cyano-4-(2,5-dichlorophenyl)phenol)